Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-PRDX3
- Development stage
- Preclinical
- Lead developer
- The First Affiliated Hospital of Baotou Medical College
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
AAV-PRDX3 is an adeno-associated virus (AAV) gene therapy vector designed to overexpress peroxiredoxin 3 (PRDX3), a major mitochondrial peroxide scavenger and antioxidant enzyme. In preclinical models of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver ischemia-reperfusion injury (LIRI), hepatic-targeted overexpression of PRDX3 via AAV-PRDX3 has been shown to alleviate oxidative stress, reduce lipid peroxidation, and inhibit hepatocyte ferroptosis. This protective effect is associated with the downregulation of p53, ACSL4, and TFR1, and the upregulation of NRF2/HO-1 and SLC7A11/GPX4 antioxidant pathways.
- Other names
- AAV-Prdx3AAV-Prdx-3AAV-Prdx 3AAV8-PRDX3AAV-8-PRDX3AAV 8-PRDX3adeno-associated virus-peroxiredoxin 3
Beyond the preview
Go deeper on AAV-PRDX3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-PRDX3.